-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Biogen, Raises Price Target to $280

Benzinga·07/21/2026 13:48:35
Listen to the news
Guggenheim analyst Brad Canino maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $260 to $280.